Vertex Pharma (VRTX): Kalydeco Miss Is Not A Game Changer - Jefferies

August 16, 2016 7:31 AM EDT
Get Alerts VRTX Hot Sheet
Price: $82.92 --0%

Rating Summary:
    28 Buy, 13 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 9 | New: 8
Trade VRTX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Vertex (NASDAQ: VRTX) after the company announced that '661/Kalydeco missed on its interim efficacy analysis in het/min CF patients.

Success would have created an opportunity to reach this large subpopulation with the dual combo and reaffirmed '661's activity (given its importance as a backbone for the triple). However, the analyst believes expectations were low, and the event does not change his overall positive CF franchise view.

No change to the price target of $107.

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $102.48 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, FDA

Related Entities

Jefferies & Co

Add Your Comment